PubRank

Hepatology international (Hepatol Int)

Journal PubWeight™ 465.87‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. 2008 5.25
2 Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 5.02
3 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. 2012 4.52
4 Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). 2008 4.16
5 Updates in the pathogenesis, diagnosis and management of ectopic varices. 2008 1.97
6 Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. 2015 1.92
7 APASL consensus statements and management algorithms for hepatitis C virus infection. 2012 1.79
8 The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. 2008 1.77
9 New antiviral therapies for chronic hepatitis C. 2010 1.71
10 Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. 2014 1.47
11 Analysis of adult 20-year survivors after liver transplantation. 2014 1.45
12 Feasibility of liver graft procurement with donor gallbladder preservation in living donor liver transplantation. 2015 1.42
13 HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. 2014 1.41
14 A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. 2014 1.41
15 Role of N-acetylcysteine in adults with non-acetaminophen-induced acute liver failure in a center without the facility of liver transplantation. 2009 1.41
16 Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. 2014 1.40
17 The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool. 2015 1.39
18 Application of the BAR score as a predictor of short- and long-term survival in liver transplantation patients. 2014 1.38
19 Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. 2015 1.37
20 Clinical features of clinically diagnosed eosinophilic liver abscesses. 2011 1.37
21 Role of free radicals in liver diseases. 2009 1.36
22 Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. 2014 1.31
23 Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. 2008 1.29
24 Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. 2007 1.24
25 Liver transplantation for acute-on-chronic liver failure. 2009 1.23
26 Non-invasive assessment of liver fibrosis in chronic hepatitis C. 2011 1.15
27 Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. 2011 1.14
28 Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. 2007 1.13
29 Role of viral factors in the natural course and therapy of chronic hepatitis B. 2007 1.13
30 HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. 2009 1.13
31 Hepatitis B reactivation after chemotherapy: two decades of clinical research. 2008 1.13
32 Immune and inflammatory pathways in NASH. 2013 1.12
33 Hepatocellular adenoma: what is new in 2008. 2008 1.12
34 The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. 2010 1.12
35 Spontaneous regression of a solitary necrotic nodule of the liver. 2010 1.10
36 Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. 2007 1.10
37 Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. 2010 1.10
38 Cirrhotic cardiomyopathy. 2008 1.07
39 Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. 2010 1.06
40 Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male. 2008 1.05
41 Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. 2010 1.05
42 Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). 2008 1.05
43 Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. 2008 1.04
44 The economics of treating chronic hepatitis B in Asia. 2008 1.04
45 Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. 2011 1.04
46 Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). 2008 1.04
47 Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. 2010 1.03
48 HBV life cycle and novel drug targets. 2011 1.03
49 Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. 2009 1.02
50 Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt. 2010 1.02
Next 50